Dexmedetomidine hydrochloride
[CAS# 145108-58-3]

Identification

• Classification: Biochemical >> Inhibitor >> Neuronal signaling >> Adrenergic receptor agonist
• Name: Dexmedetomidine hydrochloride
• Synonyms: 4-((S)-alpha,2,3-Trimethylbenzyl)imidazole monohydrochloride; 4-[(1R)-1-(2,3-Dimethylphenyl)ethyl]-3H-imidazole hydrochloride
• Molecular Formula: C₁₃H₁₆N₂.HCl
• Molecular Weight: 236.74
• CAS Registry Number: 145108-58-3
• EC Number: 682-047-2
• SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H315-H319-H335
• Safety Statements: P261-P264-P264+P265-P270-P271-P280-P301+P317-P302+P352-P304+P340-P305+P351+P338-P319-P321-P330-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Skin irritation	Skin Irrit.	2	H315
Eye irritation	Eye Irrit.	2	H319
Acute toxicity	Acute Tox.	4	H302
Specific target organ toxicity - single exposure	STOT SE	3	H335
Acute toxicity	Acute Tox.	2	H330
Acute toxicity	Acute Tox.	2	H300
Reproductive toxicity	Repr.	2	H361
Specific target organ toxicity - single exposure	STOT SE	3	H336
Acute hazardous to the aquatic environment	Aquatic Acute	1	H400
Reproductive toxicity	Lact.	-	H362
Chronic hazardous to the aquatic environment	Aquatic Chronic	1	H410
Specific target organ toxicity - repeated exposure	STOT RE	1	H372
Specific target organ toxicity - single exposure	STOT SE	1	H370
Eye irritation	Eye Irrit.	2A	H319
Acute toxicity	Acute Tox.	3	H311
Acute toxicity	Acute Tox.	3	H301

Discovery and Applications

Dexmedetomidine hydrochloride is a highly selective α₂-adrenergic receptor agonist used in clinical anesthesia and intensive care medicine for its sedative, anxiolytic, and analgesic-sparing properties. It is a hydrochloride salt form of dexmedetomidine, developed as a more refined alternative to earlier α₂-agonists such as clonidine. Its discovery and clinical introduction marked a significant advancement in the ability to provide conscious sedation without substantial respiratory depression.

Dexmedetomidine was initially synthesized in the 1980s as part of a pharmacological search for agents with more selective α₂-adrenoceptor activity. Its development was led by Orion Pharma and Abbott Laboratories (now AbbVie), and the compound received U.S. Food and Drug Administration (FDA) approval in 1999 under the trade name Precedex for the sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.

Unlike other sedatives such as benzodiazepines or propofol, dexmedetomidine induces a sedative state that closely resembles natural sleep. Its action is primarily mediated through activation of α₂-adrenergic receptors in the locus coeruleus of the brainstem, resulting in inhibition of norepinephrine release and reduced sympathetic activity. This produces sedation and analgesia while preserving respiratory function, which is a key advantage in various clinical scenarios.

Dexmedetomidine is used in several applications. In intensive care units (ICUs), it is administered by continuous intravenous infusion for sedation of mechanically ventilated patients. It is also approved for procedural sedation of non-intubated patients, such as during minor surgical or diagnostic procedures. Additionally, it has been employed off-label in pediatric sedation, awake fiberoptic intubation, and as an adjunct to general anesthesia due to its opioid-sparing and anesthetic-sparing effects.

The pharmacokinetics of dexmedetomidine support its use as an infusion-based agent. It has a distribution half-life of approximately 6 minutes and a terminal elimination half-life of around 2 hours. The drug is metabolized in the liver through direct glucuronidation and cytochrome P450-mediated oxidation, with metabolites excreted primarily via the kidneys.

In clinical trials and practice, dexmedetomidine has demonstrated a favorable safety profile. Common adverse effects include hypotension, bradycardia, and dry mouth. These effects are related to its sympatholytic mechanism and are dose-dependent. While generally well tolerated, careful titration and monitoring are necessary, especially in patients with underlying cardiovascular conditions.

The utility of dexmedetomidine has expanded globally, with approvals and guidelines for its use across various countries. In surgical settings, it is often employed to reduce the need for opioids, improve hemodynamic stability, and facilitate smooth recovery from anesthesia. It is also used in palliative care and for the management of agitation in critically ill patients.

Dexmedetomidine has also been studied in veterinary medicine for sedation and analgesia in dogs and cats, where it exhibits similar pharmacodynamic effects. In these contexts, it is used either alone or in combination with other anesthetic agents for premedication and procedural sedation.

In summary, dexmedetomidine hydrochloride is a selective α₂-adrenergic receptor agonist widely used for sedation in intensive care and procedural settings. Its ability to provide sedation without respiratory depression, along with analgesic and anxiolytic properties, makes it a versatile agent in both human and veterinary medicine. Its development represents a significant advance in sedative pharmacology and continues to influence clinical sedation practices

References

2010. High concentrations of dexmedetomidine inhibit compound action potentials in frog sciatic nerves without α2 adrenoceptor activation. British Journal of Pharmacology, 160(7).
DOI: 10.1111/j.1476-5381.2010.00833.x

2012. CYP2A6 genetic variation and dexmedetomidine disposition. European Journal of Clinical Pharmacology, 68(6).
DOI: 10.1007/s00228-011-1208-z

2024. Dexmedetomidine Attenuated Neuron Death, Cognitive Decline, and Anxiety-Like Behavior by Inhibiting CXCL2 in CA1 Region of AD Mice. Drug Design, Development and Therapy, 18.
DOI: 10.2147/dddt.s489860